Oncolytics Biotech Files Routine 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Dec 3, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
ONCO files routine 6-K, nothing major to see here.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on December 3, 2024, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is in the Pharmaceutical Preparations industry and will file its annual reports under Form 20-F. This filing does not appear to contain specific financial updates or material events beyond its routine reporting status.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is adhering to its reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not appear to contain new material information or significant financial events.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- 20241203 (date) — Filing Date
- 001-38512 (company) — SEC File Number
- Calgary, Alberta, Canada (location) — Company Headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
Which form will Oncolytics Biotech Inc. use for its annual reports?
Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was this Form 6-K filed?
This Form 6-K was filed on December 3, 2024.
Is Oncolytics Biotech Inc. submitting this Form 6-K in paper format?
The filing indicates that the registrant is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1), as that rule only permits paper submission solely to provide an attached annual report to security holders.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-12-03 11:28:46
Filing Documents
- form6kgobletc5safetyrun-in.htm (6-K) — 18KB
- gobletcohort5safetyrun-in.htm (EX-99.1) — 25KB
- 0001129928-24-000073.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date December 3, 2024 Kirk Look Chief Financial Officer